AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16507398 — intervention group
Group type: EXPERIMENTAL
Intervention: exemestane 25 mg daily and celecoxib 400 mg twice-daily (Group A)
Number of subjects: 41
Study 16507398 — intervention group
Group type: EXPERIMENTAL
Intervention: exemestane 25 mg daily (Group B)
Number of subjects: 41
Study 16507398 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole 2.5 mg daily (Group C)
Number of subjects: 41
Study 12090818 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (mean total daily dose, 3.4 mg/kg per day)
Number of subjects: 41
Study 12090818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 12090818 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 41
Study 10613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation and exercise
Number of subjects: 49
Study 10613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation as analgesic and exercise
Number of subjects: 49
Study 10613165 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 49
Study 7565526 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped music intervention
Number of subjects: 4
Study 7565526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile intervention
Number of subjects: 4
Study 7565526 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped music condition
Number of subjects: 4
Study 7565526 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no music)
Number of subjects: 4
Study 1951147 — intervention group
Group type: EXPERIMENTAL
Intervention: Large meal (LM)
Number of subjects: 7
Study 1951147 — intervention group
Group type: COMPARATOR
Intervention: Small meals (SM)
Number of subjects: 7
Study 7129746 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (obese-adolescent females)
Number of subjects: 68
Study 7129746 — intervention group
Group type: COMPARATOR
Intervention: Control condition (normal weight adolescent females)
Number of subjects: 68
Study 30632924 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-recorded clinical hypnosis intervention
Number of subjects: 170
Study 30632924 — intervention group
Group type: EXPERIMENTAL
Intervention: Music session
Number of subjects: 170
Study 30632924 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting in the room before biopsy)
Number of subjects: 170
Study 29061621 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based model of care (MoC) for FH detection and management.
Number of subjects: 0
Study 25392341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25392341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 4 µg/cc
Number of subjects: 90
Study 25392341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 8 µg/cc
Number of subjects: 90
Study 24811963 — intervention group
Group type: EXPERIMENTAL
Intervention: Aganirsen eye drops (86 μg/day/eye) applied twice daily for 90 days
Number of subjects: 69
Study 24811963 — intervention group
Group type: EXPERIMENTAL
Intervention: Aganirsen eye drops
Number of subjects: 69
Study 24811963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 23146777 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin ingestion for 8 weeks
Number of subjects: 32
Study 23146777 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training for 8 weeks
Number of subjects: 32
Study 23146777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 19151567 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR for postoperative 10 months (1,200 mg/body/day for five days followed by two days rest)
Number of subjects: 239
Study 17874490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.004% Travoprost
Number of subjects: 20
Study 17874490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15278273 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline and rifampin-impregnated catheters
Number of subjects: 465
Study 15278273 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated catheters
Number of subjects: 465
Study 11222112 — intervention group
Group type: EXPERIMENTAL
Intervention: Power spectral analysis (alpha TF)
Number of subjects: 142
Study 11222112 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine method (BS(phen))
Number of subjects: 142
Study 9603683 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home‐based moderate‐intensity physical activity regimen for four months
Number of subjects: 0
Study 9603683 — intervention group
Group type: COMPARATOR
Intervention: Physical inactivity
Number of subjects: 0
Study 7960409 — intervention group
Group type: EXPERIMENTAL
Intervention: NODS
Number of subjects: 30
Study 7960409 — intervention group
Group type: COMPARATOR
Intervention: Isopto‐NaturaleR
Number of subjects: 30
Study 2448145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination doxorubicin and mitomycin C (DM)
Number of subjects: 95
Study 2448145 — intervention group
Group type: COMPARATOR
Intervention: Combination cisplatin, vinblastine and bleomycin (PVB)
Number of subjects: 95
Study 30943497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 37
Study 30943497 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 37
Study 30943497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg plus Propranolol 40 mg
Number of subjects: 37
Study 30943497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 29208690 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.45 mg/day), n=18
Number of subjects: 67
Study 29208690 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol (50 μg/day) with oral micronized progesterone (Prometrium 200 mg), n=23
Number of subjects: 67
Study 29208690 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills and patch, n=26
Number of subjects: 67
Study 25488344 — intervention group
Group type: EXPERIMENTAL
Intervention: DC group (double-coated probiotic formulation)
Number of subjects: 40
Study 25488344 — intervention group
Group type: COMPARATOR
Intervention: NC group (non-coated probiotic formulation)
Number of subjects: 40
Study 23141486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction (DSR)
Number of subjects: 17
Study 21507257 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interview followed by visits every 2-3 weeks to the end of dose reduction
Number of subjects: 495
Study 21507257 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interview plus delivery of written instructions to self-reduce benzodiazepine dose
Number of subjects: 495
Study 21507257 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 495
Study 21507257 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 495
Study 18713842 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (METY, 3 g)
Number of subjects: 7
Study 18713842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTCZ, 1.2 g)
Number of subjects: 7
Study 18713842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 7
Study 16828435 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training (n = 13)
Number of subjects: 42
Study 16828435 — intervention group
Group type: COMPARATOR
Intervention: Cycle training (n = 15)
Number of subjects: 42
Study 16828435 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 42
Study 12816022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (including medical record review, medication history review, pharmacotherapeutic evaluation, patient medication education and monitoring over one year)
Number of subjects: 69
Study 12816022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 69
Study 12816022 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 69
Study 10234494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 5 micrograms kg‐1 min‐1
Number of subjects: 9
Study 10234494 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 9
Study 9199125 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (3.5 mg/kg) administered intravenously to humans with mixed-form hyperlipidemia
Number of subjects: 2
Study 9199125 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (12 mg/kg) administered intravenously to hyperlipidemic rabbits
Number of subjects: 2
Study 1842009 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpinia speciosa
Number of subjects: 10
Study 1842009 — intervention group
Group type: EXPERIMENTAL
Intervention: Elephantopus scaber
Number of subjects: 10
Study 1842009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6849784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chloroquine (300 mg)
Number of subjects: 11
Study 6849784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution chloroquine (300 mg)
Number of subjects: 11
Study 6849784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine tablets (300 mg)
Number of subjects: 11
Study 6849784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doses of chloroquine
Number of subjects: 11
Study 6849784 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency audiometry
Number of subjects: 11
Study 31514745 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat HIV self-testing (HIVST) under observation of a trained nurse counsellor
Number of subjects: 95
Study 31514745 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based rapid HIV testing
Number of subjects: 95
Study 31514745 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/PCR testing (considered gold-standard)
Number of subjects: 95
Study 31068019 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied 2 times per week for 3 weeks
Number of subjects: 66
Study 31068019 — intervention group
Group type: COMPARATOR
Intervention: Pressure garment (PG) 20‐60 mmHg for at least 15‐18 hours per day for 3 weeks
Number of subjects: 66
Study 27365077 — intervention group
Group type: EXPERIMENTAL
Intervention: Genta‐Coll group (G‐group)
Number of subjects: 996
Study 27365077 — intervention group
Group type: EXPERIMENTAL
Intervention: InteguSeal group (I‐group)
Number of subjects: 996
Study 27365077 — intervention group
Group type: COMPARATOR
Intervention: Standard group (S‐group)
Number of subjects: 996
Study 25455421 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 38
Study 25455421 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplementation
Number of subjects: 38
Study 25455421 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey and Soy protein groups combined
Number of subjects: 38
Study 25455421 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey and Soy protein groups
Number of subjects: 38
Study 25455421 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 38
Study 23292038 — intervention group
Group type: EXPERIMENTAL
Intervention: HA ester patching (Epifilm®)
Number of subjects: 155
Study 23292038 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous closure
Number of subjects: 155
Study 23292038 — intervention group
Group type: EXPERIMENTAL
Intervention: HA ester patching (Epifilm®) and Spontaneous closure
Number of subjects: 155
Study 22586827 — intervention group
Group type: EXPERIMENTAL
Intervention: PostureJac (SomatoCentric Systems, Inc., Toronto, Ontario, Canada)
Number of subjects: 45
Study 22586827 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 45
Study 22586827 — intervention group
Group type: COMPARATOR
Intervention: Treatment-control (table stabilization)
Number of subjects: 45
Study 19556794 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth I reconstruction
Number of subjects: 31
Study 19556794 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction
Number of subjects: 31
Study 16683432 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous iliac crest graft (group A, n=20)
Number of subjects: 60
Study 16683432 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone and anterior cervical locking plates (group B, n=20)
Number of subjects: 60
Study 16683432 — intervention group
Group type: COMPARATOR
Intervention: Syncage‐C filled with local autograft reamings (group C, n=20)
Number of subjects: 60
Study 15592329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg daily) with Dapsone (100 mg daily)
Number of subjects: 23
Study 15592329 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily) with Dapsone (100 mg daily)
Number of subjects: 23
Study 15592329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole plus Rifabutin with Dapsone (100 mg daily)
Number of subjects: 23
Study 15592329 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily) with Dapsone (100 mg daily)
Number of subjects: 23
Study 15592329 — intervention group
Group type: COMPARATOR
Intervention: Dapsone (100 mg daily) alone
Number of subjects: 23
Study 11359439 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy) for 12 months
Number of subjects: 20
Study 9644873 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of ZAM
Number of subjects: 39
Study 9644873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7937908 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite alterations in tumors
Number of subjects: 100
Study 7937908 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite alterations detection in urine, sputum, and surgical margins
Number of subjects: 100
Study 3218660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha(OH)D3 treatment (2 micrograms for 3 months)
Number of subjects: 48
Study 3218660 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study 30100304 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 40
Study 30100304 — intervention group
Group type: COMPARATOR
Intervention: Sham taping (ST)
Number of subjects: 40
Study 27785091 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A (BTX‐A) injection
Number of subjects: 29
Study 27785091 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 29
Study 25344113 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 66
Study 25344113 — intervention group
Group type: COMPARATOR
Intervention: Lepirudin
Number of subjects: 66
Study 23562583 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Being Me intervention
Number of subjects: 88
Study 23562583 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 21346512 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily DRV/r 800/100 mg
Number of subjects: 590
Study 21346512 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily DRV/r 600/100 mg
Number of subjects: 590
Study 19054926 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and loratadine
Number of subjects: 115
Study 19054926 — intervention group
Group type: COMPARATOR
Intervention: Placebo and loratadine
Number of subjects: 115
Study 17012486 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening laboratory tests for immunodeficiency
Number of subjects: 0
Study 17012486 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with a specialist
Number of subjects: 0
Study 14517728 — intervention group
Group type: EXPERIMENTAL
Intervention: Basilic vein transposition in upper arm (brachiobasilic fistula)
Number of subjects: 20
Study 14517728 — intervention group
Group type: EXPERIMENTAL
Intervention: Basilic vein transposition in forearm (radiobasilic fistula)
Number of subjects: 20
Study 10894321 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5-20 mg od
Number of subjects: 39
Study 10894321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30-90 mg od
Number of subjects: 39
Study 10894321 — intervention group
Group type: COMPARATOR
Intervention: Comparison of enalapril and nifedipine
Number of subjects: 39
Study 8815972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal cryoanalgesia
Number of subjects: 100
Study 8815972 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological analgesia ad libitum (Control)
Number of subjects: 100
Study 1422722 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 322
Study 1422722 — intervention group
Group type: COMPARATOR
Intervention: plication darn
Number of subjects: 322
Study 7402771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol (0.15 mg/kg)
Number of subjects: 16
Study 7402771 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol aerosol (0.2 mg)
Number of subjects: 16
Study 7402771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 16
Study 7402771 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol aerosol
Number of subjects: 16
Study 31818868 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medical record triggers, provider education, and peer comparison
Number of subjects: 0
Study 30481106 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial scale (CS) vaccine lot 1
Number of subjects: 1197
Study 30481106 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial scale (CS) vaccine lot 2
Number of subjects: 1197
Study 30481106 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial scale (CS) vaccine lot 3
Number of subjects: 1197
Study 30481106 — intervention group
Group type: COMPARATOR
Intervention: Pooled Commercial scale (CS) group
Number of subjects: 1197
Study 30481106 — intervention group
Group type: COMPARATOR
Intervention: Licensed pilot scale (LPS) vaccine
Number of subjects: 1197
Study 30481106 — intervention group
Group type: COMPARATOR
Intervention: All groups (CS and LPS)
Number of subjects: 1197
Study 28164777 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 80
Study 28164777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26017930 — intervention group
Group type: EXPERIMENTAL
Intervention: Child recall questionnaire
Number of subjects: 50
Study 26017930 — intervention group
Group type: COMPARATOR
Intervention: Parent recall questionnaire
Number of subjects: 50
Study 26017930 — intervention group
Group type: EXPERIMENTAL
Intervention: Child diary
Number of subjects: 50
Study 22827502 — intervention group
Group type: COMPARATOR
Intervention: Abstinent individuals at 6 months
Number of subjects: 995
Study 22827502 — intervention group
Group type: COMPARATOR
Intervention: Low-risk drinkers at 6 months
Number of subjects: 995
Study 22827502 — intervention group
Group type: COMPARATOR
Intervention: Drinking groups (abstinent, low-risk, heavy)
Number of subjects: 995
Study 21127478 — intervention group
Group type: EXPERIMENTAL
Intervention: Family functioning score ≥2
Number of subjects: 408
Study 21127478 — intervention group
Group type: EXPERIMENTAL
Intervention: Family functioning score
Number of subjects: 408
Study 19445861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg)
Number of subjects: 65
Study 19445861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 19445861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 65
Study 17226809 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic prostatectomy
Number of subjects: 200
Study 17226809 — intervention group
Group type: COMPARATOR
Intervention: Perineal prostatectomy
Number of subjects: 200
Study 16648084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial osteopathic manipulation
Number of subjects: 28
Study 16648084 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 28
Study 14665593 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised feedback on fitness and health status
Number of subjects: 299
Study 14665593 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no feedback)
Number of subjects: 299
Study 9918518 — intervention group
Group type: EXPERIMENTAL
Intervention: D allele of the ACE gene
Number of subjects: 348
Study 9918518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stroke)
Number of subjects: 348
Study 8703690 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (20 Gy in five fractions)
Number of subjects: 0
Study 8703690 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of the brain metastasis followed by postoperative radiation
Number of subjects: 0
Study 2127786 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (2 million units, subcutaneous injections three times weekly for 6 months)
Number of subjects: 41
Study 2127786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections three times weekly for 6 months)
Number of subjects: 41
Study 2127786 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (2 million units)
Number of subjects: 41
Study 7381999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (3 percent) instillation into the urethral catheter drainage bag
Number of subjects: 31
Study 7381999 — intervention group
Group type: COMPARATOR
Intervention: Conventional drainage
Number of subjects: 31
Study 7381999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (3 percent) instillation
Number of subjects: 31
Study 29543135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF)
Number of subjects: 14
Study 29543135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28302422 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic protocol with community care referral
Number of subjects: 5914
Study 28302422 — intervention group
Group type: COMPARATOR
Intervention: Control care as usual
Number of subjects: 5914
Study 26161000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group V (vehicle onboard cognitive training program)
Number of subjects: 37
Study 26161000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (personal computer cognitive training program)
Number of subjects: 37